Psychological and physiological effects of bupropion compared to methylphenidate after prolonged administration in healthy volunteers (NCT00285155)

European Journal of Clinical Pharmacology

Volumn 69, Issue 4, 2013, Pages 779-787

  Chevassus, Hugues ^a,b,d   Farret, Anne ^a,b   Gagnol, Jean Pierre ^a,b   Ponçon, Claire Anne ^a,b   Costa, Françoise ^a,b   Roux, Clarisse ^a,b   Galtier, Florence ^a,b,c   Petit, Pierre ^a,b,c  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIV MONTPELLIER   (France)

^d HÔPITAL SAINT ELOI   (France)

Author keywords

Autonomic effects; Bupropion; Clinical trial; Human; Psychomotor performance; Subjective feelings

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; METHYLPHENIDATE; PLACEBO;

ADULT; ANOREXIA; ANXIETY; APPETITE; ARTICLE; ASTHENIA; ATTENTION DISTURBANCE; BODY TEMPERATURE; COGNITION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG ADMINISTRATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG WITHDRAWAL; EMOTION; ENERGY CONSUMPTION; FATIGUE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERACTIVITY; IMPULSIVENESS; INCREASED APPETITE; IRRITABILITY; MALE; MOOD DISORDER; NORMAL HUMAN; NOSE DISEASE; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PRIORITY JOURNAL; PROLONGED DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP DISORDER; SMOKING CESSATION; THROAT DISEASE; WEIGHT REDUCTION;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BLOOD PRESSURE; BODY TEMPERATURE; BUPROPION; COGNITION; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENERGY INTAKE; HUMANS; MALE; METHYLPHENIDATE; PSYCHOMOTOR PERFORMANCE; TIME FACTORS; YOUNG ADULT;

EID: 84876703918     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1418-z     Document Type: Article

References (41)

1. Preskorn SH, Othmer SC (1984) Evaluation of bupropion hydrochloride: the first of a new class of atypical antidepressants. Pharmacotherapy 4(1):20-34
2. Hughes JR, Stead LF, Lancaster T (2007) Antidepressants for smoking cessation. Cochrane Database Syst Rev (1):CD000031
3. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E et al (1995) Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56(9):395-401
4. Cooper BR, Hester TJ, Maxwell RA (1980) Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo. J Pharmacol Exp Ther 215(1):127-134
5. Arias HR (2009) Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions? Int J Biochem Cell Biol 41(11):2098-2108
6. Munzar P, Goldberg SR (2000) Dopaminergic involvement in the discriminative-stimulus effects of methamphetamine in rats. Psychopharmacology (Berl) 148(2):209-216
7. Reichel CM, Murray JE, Grant KM, Bevins RA (2009) Bupropion attenuates methamphetamine self-administration in adult male rats. Drug Alcohol Depend 100(1-2):54-62
8. Lamb RJ, Griffiths RR (1990) Self-administration in baboons and the discriminative stimulus effects in rats of bupropion, nomifensine, diclofensine and imipramine. Psychopharmacology (Berl) 102(2):183-190
9. Bergman J, Madras BK, Johnson SE, Spealman RD (1989) Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. J Pharmacol Exp Ther 251(1):150-155
10. Bredeloux P, Dubuc I, Costentin J (2007) Comparisons between bupropion and dexamphetamine in a range of in vivo tests exploring dopaminergic transmission. Br J Pharmacol 150(6):711-719
11. Hamilton MJ, Smith PR, Peck AW (1983) Effects of bupropion, nomifensine and dexamphetamine on performance, subjective feelings, autonomic variables and electroencephalogram in healthy volunteers. Br J Clin Pharmacol 15(3):367-374
12. Peck AW, Hamilton M (1983) Psychopharmacology of bupropion in normal volunteers. J Clin Psychiatry 44(5 Pt 2):202-205
13. Rush CR, Kollins SH, Pazzaglia PJ (1998) Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-amphetamine-trained humans. Exp Clin Psychopharmacol 6(1):32-44
14. Barrickman LL, Perry PJ, Allen AJ, Kuperman S, Arndt SV, Herrmann KJ, Schumacher E (1995) Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34(5):649-657
15. Wilens TE, Spencer TJ, Biederman J, Girard K, Doyle R, Prince J, Polisner D, Solhkhah R, Comeau S, Monuteaux MC, Parekh A (2001) A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 158(2):282-288
16. Kollins SH, MacDonald EK, Rush CR (2001) Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Behav 68(3):611-627
17. OMS (1993) Troubles mentaux et troubles deu comportement. Description clinique et directives pour le diagnostic. In: Classification Internationale des Maladies, Dixième révision (CIM-10). Masson, Paris
18. Martin WR, Sloan JW, Sapira JD, Jasinski DR (1971) Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12(2):245-258
19. McNair D, Lorr M, Droppleman LF (1971/1992) Manual for the Profile of Mood States. Edits/Educational ans Industrial Testing Service, San Diego
20. Norcross JC, Guadagnoli E, Prochaska JO (1984) Factor structure of the Profile of Mood States (POMS): two partial replications. J Clin Psychol 40(5):1270-1277
21. Norris H (1971) The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology 10(21):181-191
22. Bond A, Lader M (1974) Use Of Analog Scales In Rating Subjective Feelings. British Journal Of Medical Psychology 47:211-218
23. Parrott AC, Hindmarch I (1980) The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations - a review. Psychopharmacology (Berl) 71(2):173-179
24. Hindmarch I (1980) Psychomotor function and psychoactive drugs. Br J Clin Pharmacol 10(3):189-209
25. Ridout F, Shamsi Z, Meadows R, Johnson S, Hindmarch I (2003) A single-center, randomized, double-blind, placebo-controlled, crossover investigation of the effects of fexofenadine hydrochloride 180 mg alone and with alcohol, with hydroxyzine hydrochloride 50 mg as a positive internal control, on aspects of cognitive and psychomotor function related to driving a car. Clin Ther 25(5):1518-1538
26. Sherwood N (1995) Comparative Behavioural Toxicity of the Selective Serotonin Reuptake Inhibitors. Human Psychopharmacology 10:S159-S162
27. Smith JM, Misiak H (1976) Critical flicker frequency (CFF) and psychotropic drugs in normal human subjects-a review. Psychopharmacologia 47(2):175-182
28. Stroop JR (1935) Studies of interference in serial verbal reactions. J Exp Psychol 18(6):643-662
29. Wechsler D (1955) A manual for the Wechsler Adult Intelligence Scale. The Psychological Corporation, New York
30. Simard M, van Reekum R (1999) Memory assessment in studies of cognition-enhancing drugs for Alzheimer's disease. Drugs Aging 14(3):197-230
31. Raben A, Tagliabue A, Astrup A (1995) The reproducibility of subjective appetite scores. Br J Nutr 73(4):517-530
32. Gobbi G, Slater S, Boucher N, Debonnel G, Blier P (2003) Neurochemical and psychotropic effects of bupropion in healthy male subjects. J Clin Psychopharmacol 23(3):233-239
33. Siepmann M, Werner K, Schindler C, Oertel R, Kirch W (2005) The effects of bupropion on cognitive functions in healthy subjects. Psychopharmacology (Berl) 182(4):597-598
34. Carvalho AF, Kohler CA, Cruz EP, Sturmer PL, Reichman BP, Barea BM, Izquierdo I, Chaves ML (2006) Acute treatment with the antidepressants bupropion and sertraline do not influence memory retrieval in man. Eur Arch Psychiatry Clin Neurosci 256(5):320-325
35. Griffith JD, Carranza J, Griffith C, Miller LL (1983) Bupropion: clinical assay for amphetamine-like abuse potential. J Clin Psychiatry 44(5 Pt 2):206-208
36. Miller L, Griffith J (1983) A comparison of bupropion, dextroamphetamine, and placebo in mixed-substance abusers. Psychopharmacology (Berl) 80(3):199-205
37. Newton TF, Roache JD, De La Garza R 2nd, Fong T, Wallace CL, Li SH, Elkashef A, Chiang N, Kahn R (2006) Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 31(7):1537-1544
38. Heil SH, Holmes HW, Bickel WK, Higgins ST, Badger GJ, Laws HF, Faries DE (2002) Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 67(2):149-156
39. Bishop C, Roehrs T, Rosenthal L, Roth T (1997) Alerting effects of methylphenidate under basal and sleep-deprived conditions. Exp Clin Psychopharmacol 5(4):344-352
40. Newton TF, Roache JD, De La Garza R 2nd, Fong T, Wallace CL, Li SH, Elkashef A, Chiang N, Kahn R (2005) Safety of intravenous methamphetamine administration during treatment with bupropion. Psychopharmacology (Berl) 182(3):426-435
41. Wilens TE, Hammerness PG, Biederman J, Kwon A, Spencer TJ, Clark S, Scott M, Podolski A, Ditterline JW, Morris MC, Moore H (2005) Blood pressure changes associated with medication treatment of adults with attention-deficit/ hyperactivity disorder. J Clin Psychiatry 66(2):253-259